Kala Bio KALA
NASDAQ KALA
$0.17 +0.02 (+9.71%)
As of: Nov 9, 2026 · 10:49 AM EST

Kala Bio (KALA) Gains (Losses) on Sale of Assets & Investments (2022)

Updated

Analysis

Kala Bio (KALA) Gains (Losses) on Sale of Assets & Investments (2022) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Gains on Sales (Qtr)
1 Eli Lilly 1,249.15 Bn 1,222.76 Bn 20.46 Bn -
2 Johnson & Johnson 672.28 Bn 592.14 Bn 17.30 Bn -
3 AbbVie 515.12 Bn 483.13 Bn 13.12 Bn -
4 Merck 364.35 Bn 327.29 Bn 13.19 Bn -
5 Novartis Ag 315.18 Bn 288.42 Bn - -
6 Astrazeneca 292.81 Bn 266.70 Bn 13.26 Bn -
7 Amgen 249.17 Bn 200.82 Bn 7.58 Bn -
8 Gilead Sciences 210.23 Bn 185.34 Bn 6.73 Bn -
9 Pfizer 165.64 Bn 113.00 Bn 12.56 Bn -
10 Kala Bio 2.61 Mn -42.03 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2022 47.00 Mn
API Access

Kala Bio Gains (Losses) on Sale of Assets & Investments API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=non-operating-investment-income&ticker=KALA&period=max&api_key=YOUR_API_KEY